The efficacy of Yiqi Huoxue therapy for chronic heart failure: A meta-analysis in accordance with PRISMA guideline.
Miao ZhangMing-Yue SunHui-Jun YinZheng-Zhi WuYu JinMa MinFeng-Qin XuPublished in: Medicine (2022)
YQHX is a valid complementary and alternative therapy in the management of CHF, especially in improving overall response rate, TCM syndrome response rate, 6-minute walk test, left ventricular ejection fraction, and stroke volume and in decreasing TCM syndrome scores, Minnesota Living with Heart Failure questionnaire, 6-month readmission rate, B-type natriuretic peptide, NT-proBNP, and C-reactive protein levels. Hence, YQHX is a relatively effective and safe therapy for CHF patients, which can be popularized and applied in the clinic. More long-term follow-up studies are still needed to substantiate and confirm the current findings.
Keyphrases
- ejection fraction
- aortic stenosis
- heart failure
- left ventricular
- atrial fibrillation
- case report
- primary care
- end stage renal disease
- acute myocardial infarction
- cross sectional
- randomized controlled trial
- mesenchymal stem cells
- patient reported
- patient reported outcomes
- cell therapy
- transcatheter aortic valve replacement
- coronary artery disease
- acute heart failure